Neglected Again: ODA Cuts Threaten Global Progress on Tropical Diseases Neglected tropical diseases (NTDs) continue to plague over a billion people around the world, predominantly affecting vulnerable populations in low-resource settings across Africa, Asia, and Latin America. These diseases —…
Biotech Industry Sounds Alarm on Trump Tariffs, Citing Threats to Rare Disease and Advanced Therapies Despite billions of dollars being funneled into reshoring pharmaceutical manufacturing to U.S. soil, the biotech industry is sounding the alarm over looming tariffs proposed by…
BioNTech and Bristol Myers Squibb Forge $11.1 Billion Global Partnership to Advance Bispecific Cancer Antibody BNT327 Across Multiple Solid Tumor Types In a move that signals a major step forward in the fight against some of the most challenging forms…
Genmab Unveils Promising Phase 1/2 Data for Rina-S® in Heavily Pretreated Advanced Endometrial Cancer at ASCO 2025 Genmab A/S, a leading biotechnology company specializing in antibody-based therapies for cancer, has announced new clinical data from the Phase 1/2 RAINFOL™-01 trial…
BeOne Medicines Showcases Early Clinical Success of Two Innovative Breast Cancer Therapies at ASCO 2025 BeOne Medicines Ltd. a global biotechnology company dedicated to developing targeted therapies for cancer, announced promising new data from two early-stage breast cancer drug candidates…
Traditional Medicine Moves to the Forefront at 78th World Health Assembly, Paving the Way for Global Integration Traditional medicine—long an integral part of diverse cultures and communities across the globe—commanded unprecedented attention at the 78th World Health Assembly (WHA78), held…
Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal, Expanding Rare Immunological Disease Portfolio and Deepening Immunology Pipeline In a landmark move to expand its presence in rare immunological diseases and strengthen its early-stage pipeline, French pharmaceutical giant Sanofi announced…
AbbVie and the Chicago Cubs Launch Multi-Year “Striking Out Cancer” Campaign to Support Cancer Awareness and Research In a bold and heartfelt effort to turn America’s favorite pastime into a platform for cancer advocacy, AbbVie,a global biopharmaceutical company headquartered in…
Teva Embarks on Acceleration Phase of “Pivot to Growth” Strategy at 2025 Innovation & Strategy Day, Signaling Renewed Focus on Biopharmaceutical Leadership and Long-Term Shareholder Value Teva Pharmaceutical Industries Ltd.one of the world’s leading manufacturers of generic and specialty medicines,…
Intellia Grapples with Safety Questions in ATTR Gene Editing Trial Amid Broader Sector Scrutiny Intellia Therapeutics’ stock took a steep dive Thursday morning, shedding approximately 26% of its value after the company disclosed a serious adverse event in its ongoing…
Biogen and City Therapeutics Forge Strategic Partnership to Pioneer Next-Generation RNAi-Based Therapies Targeting Central Nervous System Diseases Biogen,a global leader in neuroscience and neurodegenerative disease research, and City Therapeutics, Inc., a private biopharmaceutical company at the forefront of RNA interference…
AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with the drug receiving a positive recommendation from the Committee for…